Key points are not available for this paper at this time.
Design
Editorial
No takes yet. Share an insight, caveat, or question.
The authors advocate for US and European regulators to mandate plasma monitoring for dabigatran due to bleeding safety concerns.
Moore et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: